Kano Therapeutics is a founder-led biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them, empowering scientists, labs, and companies with the building blocks they need to cross the chasm to cures.
Location: United States, Massachusetts, Cambridge
Total raised: $7.1M
Investors 1
| Date | Name | Website |
| - | Engine Ven... | enginevent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2024 | Seed | $7.1M | - |
Mentions in press and media 3
| Date | Title | Description |
| 12.08.2024 | Kano Therapeutics Secures $7.1M | CAMBRIDGE, MA, Kano Therapeutics, a biotechnology company, has secured an oversubscribed $5 million seed round. >> Click here for more funding data on Kano Therapeutics >> To export Kano Therapeutics funding data to PDF and Exc... |
| 12.08.2024 | Kano Therapeutics Raises $5M in Seed Funding | Kano Therapeutics, a Cambridge, MA-based biotechnology company advancing single-stranded DNA (ssDNA) as a flexible biomolecule for gene insertions, raised $5M in Seed funding. The round, which brought the total amount to $7.1M, was led by T... |
| - | Kano Therapeutics | “KANO” |